Live

FierceBiotechGLP-1s may combat depression by multiplying a mood-boosting gut microbe Endpoints NewsSonoThera raises $125M for non-viral gene therapy approach BioPharma DiveParabilis sets a record with a $670M biotech IPO FierceBiotechBig Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery Clinical OMICsGLP-1s May Benefit Mental Health Through Gut–Brain Axis Clinical OMICsPhase Ib/IIa for Hepatitis B Epigenetic Silencer Shows Best-in-Class Potential FierceBiotechEthyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza Endpoints NewsShattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation Endpoints NewsBiotech pay analysis: 12 execs with $35M+ M&A golden parachutes BioPharma DiveAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B BioWorldShenzhen Chipscreen Biosciences synthesizes new HDAC inhibitors

Labiotech Jun 10, 2026

How Daiichi Sankyo aims to become a top five oncology player by 2035

Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to bec...

Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to become a top five oncology player by 2035 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.